The effect of systemic acetazolamide administration on intraocular pressure in healthy horses—A preliminary study
Veterinary Ophthalmology · 2025
DOI: 10.1111/vop.13240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Ophthalmology, 2025. Verfasst von Anat Shnaiderman-Torban und 9 weiteren Autor:innen. Beteiligte Einrichtung: Koret School of Veterinary Medicine (KSVM), The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Reh…. Hauptthemen laut MEDLINE: Acetazolamide, Intraocular Pressure, Carbonic Anhydrase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
In equine glaucoma, topical treatment with carbonic anhydrase inhibitors (CAIs) is recommended. Oral acetazolamide, a systemic CAI, is used in horses with hyperkalemic periodic paralysis. Information regarding its effect on equine intraocular pressure (IOP) is scarce. The aim of the study was to determine the effect of oral acetazolamide treatment on IOP in horses, in a case–control study. Animals Ten healthy horses. Procedures Horses were treated with oral acetazolamide (4.4 mg/kg) BID for 1 week. Serum acetazolamide concentrations were determined by liquid chromatography/tandem mass spectrometry, and IOP were measured before treatment, daily during treatment, and at 48 and 72 h after treatment.
Results
Acetazolamide serum levels reached steady state at 72 h after the first oral dose. In a mixed effect model logistic regression, there was a significant decrease in IOP on the third treatment day, of 2.4 mmHg ( p = .012) and 2.7 mmHg ( p = .006) in the left (OS) and right eye (OD), respectively. On the seventh day, there was a decrease in 2.5 mmHg ( p = .008) and 2.7 mmHg ( p = .007) OS and OD, respectively. A significant increase occurred 48 h following treatment discontinuation (3.6 mmHg, p < .001 and 3.5 mmHg, p < .001 OS and OD, respectively). The area under the concentration versus time curve (AUC (0–10h) ) was 1.1 ± 0.5 μg/mL*h, mean residence time 6.7 ± 4.3 h, peak plasma concentration ( C max ) 0.4 ± 0.4 μg/mL and time to reach C max 1.8 h. There was a significant increase in serum concentrations 1, 2, 48, 72, and 156 h following the first drug administration ( p < .05).
Conclusions
Further studies are required to determine whether acetazolamide is a potential treatment for equine glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koret School of Veterinary Medicine (KSVM), The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel.
- Department of Veterinay Medicine and Animal Sciences, University of Milan, Lodi, Italy.
- Kimron Veterinary Institute, Bet Dagan, Israel.
- Hadassah Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
ORCID-Profile: Anat Shnaiderman-Torban, Ron Ofri
Zitieren
APA
Shnaiderman-Torban, A., Pe'er, O., Gustafsson, K., Tatz, A., Brizi, M., Soback, S., Abu Ahmad, W., Magen, R., Ofri, R., & Kelmer, G. (2025). The effect of systemic acetazolamide administration on intraocular pressure in healthy horses—A preliminary study. Veterinary Ophthalmology. https://doi.org/10.1111/vop.13240
Vancouver
Shnaiderman-Torban A, Pe'er O, Gustafsson K, Tatz A, Brizi M, Soback S, et al. The effect of systemic acetazolamide administration on intraocular pressure in healthy horses—A preliminary study. Veterinary Ophthalmology. 2025. doi:10.1111/vop.13240
BibTeX
@article{ShnaidermanTorban2025,
author = {Shnaiderman-Torban, Anat and Pe'er, Oren and Gustafsson, Kajsa and Tatz, Amos and Brizi, Malka and Soback, Stefan and Abu Ahmad, Wiessam and Magen, Ramon and Ofri, Ron and Kelmer, Gal},
title = {The effect of systemic acetazolamide administration on intraocular pressure in healthy horses—A preliminary study},
journal = {Veterinary Ophthalmology},
year = {2025},
doi = {10.1111/vop.13240}
}
EUVIMED